– USA, CA – Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced the appointment of biotech leader Dr. Damien McDevitt, Ph.D., to its Board of Directors as President and CEO.
“We are excited to welcome Damien to Aspen Neuroscience at a pivotal moment of growth and development for the company,” said Board Chairman, Faheem Hasnain. “His experience leading global teams through transformational periods will be critical to Aspen as we move into this new stage.”
About Dr. Damien McDevitt
A distinguished leader in the biotech and pharmaceutical industry sectors, Dr. McDevitt is recognized for his vision, strategic planning, and corporate leadership. With a career spanning more than 25 years, he has served in multiple boards and executive leadership roles including most recently as CEO of rare diseases company Akcea Therapeutics, Inc. Before joining Akcea, Damien held senior executive roles at Ionis Pharmaceuticals, Acadia Pharmaceuticals, and GlaxoSmithKline Pharmaceuticals.
“I am honored to be joining Aspen Neuroscience, which is innovating at the intersection of regenerative medicine and neurosciences,” said Dr. McDevitt. “I’m excited about our mission to develop transformational medicines for Parkinson’s patients, who have very limited treatment options. Aspen is poised for its next chapter, with a very compelling pipeline developed by the great minds at Scripps, including lead product ANPD001, currently undergoing IND-enabling studies for the treatment of sporadic forms of Parkinson’s disease, and ANPD002, which combines gene correction and autologous neuron therapy, being studied for the treatment of genetic forms of Parkinson’s disease. We are excited to be building this world-class team in San Diego, a hub for R&D and life sciences, and in California, which is on the leading edge of regenerative medicine science.”
About Aspen Neuroscience
Aspen Neuroscience, Inc. is a development stage, a private biotechnology company that uses innovative genomic approaches combined with stem cell biology to develop patient-specific, restorative cell therapies to modify the course of Parkinson’s disease. We strive to develop best-in-class methods for autologous neuron replacement using induced-pluripotent stem cells to address diseases with high unmet clinical needs, beginning with Parkinson’s disease and extending across the brain and affected organs.
Founded on the groundbreaking research of world-renowned stem cell scientist, Dr. Jeanne Loring, and her colleague, Dr. Andrés Bratt-Leal, Aspen was founded in 2018 and has reached critical milestones in a short span. This includes identifying and advancing two potential treatments in pre-clinical development and raising more than $76 million with broad biotech investment community support, including the recently closed Series A funding round, and a recently expanded board to include seasoned industry executives.
For more information: https://www.aspenneuroscience.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
